United Therapeutics Corporation Net Cash Provided by (Used in) Investing Activities, Continuing Operations
United Therapeutics Corporation (UTHR) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$165.60 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-04-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-04-26
- United Therapeutics Corporation net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$165.60M, a 1480.00% decline year-over-year.
- United Therapeutics Corporation net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $8.50M, a 84.96% decline year-over-year.
- United Therapeutics Corporation net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $20.10M, a 94.22% decline year-over-year.
- United Therapeutics Corporation net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $7.70M, a 75.24% decline year-over-year.
- United Therapeutics Corporation net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $48.30M, a 90.41% decline from fiscal 2015.
- United Therapeutics Corporation net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $503.60M, a 48.77% increase from fiscal 2014.
- United Therapeutics Corporation net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $338.50M.
- United Therapeutics Corporation net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$294.97M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-03-31 | -$165.60M 10-Q · filed 2017-04-26 | -$157.10M derived: sum of 2 quarters · filed 2017-04-26 | -$137.00M derived: sum of 3 quarters · filed 2017-04-26 | -$129.30M derived: sum of 4 quarters · filed 2017-04-26 | ||||
| 2016-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $28.60M derived: sum of 2 quarters · filed 2017-02-22 | $36.30M derived: sum of 3 quarters · filed 2017-02-22 | $48.30M 10-K · filed 2017-02-22 | ||||
| 2016-09-30 | $20.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $27.80M derived: sum of 2 quarters · filed 2016-10-27 | $39.80M 10-Q · filed 2016-10-27 | $96.30M derived: sum of 4 quarters · filed 2017-04-26 | ||||
| 2016-06-30 | $7.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $19.70M 10-Q · filed 2016-07-28 | $76.20M derived: sum of 3 quarters · filed 2017-04-26 | $423.80M derived: sum of 4 quarters · filed 2017-04-26 | ||||
| 2016-03-31 | $12.00M 10-Q · filed 2017-04-26 | $68.50M derived: sum of 2 quarters · filed 2017-04-26 | $416.10M derived: sum of 3 quarters · filed 2017-04-26 | $447.20M derived: sum of 4 quarters · filed 2017-04-26 | ||||
| 2015-12-31 | $56.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $404.10M derived: sum of 2 quarters · filed 2017-02-22 | $435.20M derived: sum of 3 quarters · filed 2017-02-22 | $503.60M 10-K · filed 2017-02-22 | $503.58M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $347.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $378.70M derived: sum of 2 quarters · filed 2016-10-27 | $447.10M 10-Q · filed 2016-10-27 | $447.17M 10-Q · filed 2015-10-27 | $499.09M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-06-30 | $31.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $99.50M 10-Q · filed 2016-07-28 | $99.52M 10-Q · filed 2015-07-28 | $151.49M derived: sum of 3 quarters · filed 2017-02-22 | $249.44M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-03-31 | $68.40M 10-Q · filed 2016-04-28 | $68.45M 10-Q · filed 2015-04-28 | $120.39M derived: sum of 2 quarters · filed 2017-02-22 | $218.34M derived: sum of 3 quarters · filed 2017-02-22 | $300.52M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $51.99M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $149.94M derived: sum of 2 quarters · filed 2017-02-22 | $232.12M derived: sum of 3 quarters · filed 2017-02-22 | $338.50M 10-K · filed 2017-02-22 | $338.46M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $97.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $180.13M derived: sum of 2 quarters · filed 2015-10-27 | $286.51M 10-Q · filed 2015-10-27 | $130.15M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $82.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | $188.56M 10-Q · filed 2015-07-28 | $32.20M derived: sum of 3 quarters · filed 2016-02-25 | -$143.62M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $106.38M 10-Q · filed 2015-04-28 | -$49.97M derived: sum of 2 quarters · filed 2016-02-25 | -$225.80M derived: sum of 3 quarters · filed 2016-02-25 | -$199.23M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | -$156.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$332.18M derived: sum of 2 quarters · filed 2016-02-25 | -$305.61M derived: sum of 3 quarters · filed 2016-02-25 | -$294.97M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | -$175.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | -$149.26M derived: sum of 2 quarters · filed 2014-10-28 | -$138.62M 10-Q · filed 2014-10-28 | -$303.32M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $26.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $37.20M 10-Q · filed 2014-07-29 | -$127.50M derived: sum of 3 quarters · filed 2015-02-24 | -$79.88M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $10.63M 10-Q · filed 2014-04-29 | -$154.06M derived: sum of 2 quarters · filed 2015-02-24 | -$106.45M derived: sum of 3 quarters · filed 2015-02-24 | -$106.74M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | -$164.70M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$117.08M derived: sum of 2 quarters · filed 2015-02-24 | -$117.37M derived: sum of 3 quarters · filed 2015-02-24 | -$163.36M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $47.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $47.33M derived: sum of 2 quarters · filed 2013-10-29 | $1.34M 10-Q · filed 2013-10-29 | |||||
| 2012-06-30 | -$287.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$46.28M 10-Q · filed 2013-07-25 | ||||||
| 2012-03-31 | -$45.99M 10-Q · filed 2013-04-25 | |||||||
| 2011-12-31 | -$121.33M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |